CN101036638A - Application of glycyrrhizin in the preparation of medicine for preventing and curing tumour - Google Patents
Application of glycyrrhizin in the preparation of medicine for preventing and curing tumour Download PDFInfo
- Publication number
- CN101036638A CN101036638A CN 200610038887 CN200610038887A CN101036638A CN 101036638 A CN101036638 A CN 101036638A CN 200610038887 CN200610038887 CN 200610038887 CN 200610038887 A CN200610038887 A CN 200610038887A CN 101036638 A CN101036638 A CN 101036638A
- Authority
- CN
- China
- Prior art keywords
- glycyrrhizin
- cancer
- cell
- medicine
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine art, in particular relates to an application of active material glycyrrhizin from natural plant liquorice for preparing drugs for preventing and treating cancer. The drug for treating cancer is used to treat and prevent various cancers such as lung cancer, liver cancer, gastric cancer, colon cancer, etc.
Description
Relate to the field
The present invention relates to field of medicaments, specifically, the glycyrrhizin preparation that the present invention relates to the flavanone monomeric compound glycyrrhizin (Liquiritigenin) that will extract in the liquorice root or synthetic is used for preventing the application with the medicine for treating tumor thing.
Background technology
Since the seventies in 20th century, the cancer morbidity of China is in rising trend always, about 2,000,000 people of number of the infected of the annual cancer of present China, the number of dying from cancer surpasses 1,400,000 people, wherein, the PLC mortality rate is positioned at the 3rd of cancer mortality, has every year 110000 people to die from hepatocarcinoma, accounts for 45% of world's PLC mortality sum.China's hepatocarcinoma situation occurred frequently is very serious, and China has 1.3 hundred million HBV carriers approximately at present, and 25% virus carrier is developed into chronic hepatitis, liver cirrhosis and hepatocarcinoma the most at last.WHO expects the year two thousand twenty, and 2,000 ten thousand new cases of cancers can take place every year, and wherein great majority are in developing country.To this, the cancer that China proposes the emphasis prevention is followed successively by pulmonary carcinoma, hepatocarcinoma, gastric cancer, the esophageal carcinoma, colorectal cancer, breast carcinoma, cervical cancer and nasopharyngeal carcinoma, and their totals account for 80% of the cancer cause of the death.Face cancer challenge occurred frequently.Generation and development by the chemical cancer-resisting substance prophylaxis of cancer in the research natural plants have become a key areas of cancer chemoprophylaxis research, and are subjected to the common concern of countries in the world scientific circles.
Liquorice root is abundant in china natural resources, and Radix Glycyrrhizae has multiple pharmacological function and body-care effect, it by Ministry of Public Health list in be food be again the health food list of medicine.Radix Glycyrrhizae is important simply conventional Chinese medicine in the Chinese medicine preparation of tcm clinical practice treatment tumour patient, inquires into the important directions that the monomer component that has anti-tumor activity in the Radix Glycyrrhizae is research.Though it is not many chemical analysis persons have carried out the analysis of system from chemico-analytic angle to licorice ingredient, still comprehensive for the research of the anticancer active constituent that exists in the Radix Glycyrrhizae.Research at present thinks that triterpenes and flavone compound are the antineoplastic main active in the Radix Glycyrrhizae, wherein the research of Radix Glycyrrhizae triterpenoid compound glycyrrhizic acid and glycyrrhizin antineoplastic is more, discover as Huang Wei etc., after triterpenes monomer glycyrrhizic acid concentration was 2.5mmol/L, 5mmol/L, 10mmol/L effect hepatoma carcinoma cell 96h, cell proliferation inhibition rate was respectively 32.2%, 59.4%, 85.1%
[1]And seldom, and be licoflavone class mixture, non-flavonoid monomeric compound to the research of liquorice flavonoids compound antitumaous effect.For example Fu is that force etc. discovers that licoflavone class mixture has anticancer, mutation and antioxidation, thinks that licoflavone gets a good chance of developing into the medicine of an effective prophylaxis of tumours
[2]Japan Hatano discovers that licoflavone class material can cause hepatocarcinoma and the morphologic variation of mice ehrlich ascites cell on the rat abdomen
[3]Glycyrrhizin belongs to the flavanone chemical compound, and research report glycyrrhizin in the past has antivirus action, have the effect for the treatment of infected by HIV and chronic hepatitis C virus as Radix Glycyrrhizae, also has the effect of anti AIDS virus
[4], over the past two years, researchs such as Crance found again that glycyrrhizin can suppress duplicating of SARS associated coronavirus
[5], but up to now, do not see as yet that for glycyrrhizin antitumor action and Study on Mechanism thereof report is arranged.
Summary of the invention:
Purpose of the present invention just provides in a kind of liquorice root to be extracted or the flavanone monomeric compound glycyrrhizin (Liquiritigenin) of synthetic is used for preventing and treating the application of curing oncoma medicine in preparation, described curing cancer drug be used for the treatment of and prevent hepatocarcinoma, pulmonary carcinoma, gastric cancer, colon cancer, leukemia, etc. multiple cancer.
Purpose of the present invention, advantage etc. will illustrate by the non-limitative illustration of following preferential embodiment and explain that these embodiment only provide as an example with reference to accompanying drawing.
Description of drawings
Fig. 1 is the dose-response relationship sketch map for showing glycyrrhizin 200 μ mol/L, 300 μ mol/L, 400 μ mol/L, 500 μ mol/L to the inhibition of liver cancer cell growth.
Fig. 2 is the inhibitory action sketch map of glycyrrhizin to colon cancer cell
The specific embodiment
Shown in Fig. 1, Fig. 2 and table 1, table 2, table 3, table 4, table 5, table 6, in the research process of the present invention, carried out the screening experiment of external different tumor cells, comprise human lung cancer cell A549, gastric carcinoma cells (SGC7901), human liver cancer cell (SMMC7721), human colon cancer cell (LOVO), human promyelocytic leukemia cell HL-60, through repeatedly screening, find that glycyrrhizin has the effect of obvious anticancer growth, and being dose-response relationship, PRELIMINARY RESULTS provides good basis for the further investigation of this project.
One, cell strain and screening technique
[cell strain] human lung cancer cell A549
The low differentiation of people adenocarcinoma of stomach cell BGC-823
Human liver cancer cell SMMC-7721
Human promyelocytic leukemia cell HL-60
[method]
1. get and be in one bottle in cell in good condition exponential phase of growth, add 0.25% tryptic digestive juice, digestion comes off attached cell, counting 2-4 * 10
4Individual/ml, make cell suspension.
2. obtained cell suspension is inoculated on 96 orifice plates, and 180/ hole is put in the constant temperature CO2 incubator and cultivated 24 hours.
3. change liquid, adding is subjected to the reagent thing, and cultivated 72 hours in 20/ hole.
4. MTT is added in 96 orifice plates, cultivated 4 hours in the incubator in 20/ hole.
5. inhale and remove supernatant, add DMSO, 150/ hole, jolting is 5 minutes on the dull and stereotyped shaking table.
6. measure the light absorption value in every hole with enzyme-linked immunosorbent assay instrument at wavelength 570nm place, and calculate cell inhibitory rate.
Table 1 anti-tumor activity criterion
| Known molecular quantizes compound mol/L | Unknown compound μ g/ml | Crude extract μ g/ml | Cell inhibitory rate % | Active |
| 1×10 -71×10 -61×10 -51×10 -71×10 -61×10 -51×10 -71×10 -61×10 -5 | 1 10 100 1 10 100 1 10 100 | 2 20 200 2 20 200 2 20 200 | ≥50 ≥50 ≥50 ＜50 ≥50 ≥50 ＜50 ＜50 ≥50 | +++potent ++ the weak effect of middle effect |
Two, The selection result
Table 2 glycyrrhizin is to the inhibitory action of cancerous cell
| Sample | Final concentration μ g/ml | Human liver cancer cell SMMC-7721 | The human lung cancer cell A549 | The low differentiation of people adenocarcinoma of stomach cell BGC-823 | Human promyelocytic leukemia cell HL-6 | ||||
| Suppression ratio % | Active | Suppression ratio % | Active | Suppression ratio % | Active | Suppression ratio % | Active | ||
| Glycyrrhizin | 1 10 100 | 23.17 96.08 98.00 | ++ | 7.76 35.66 93.03 | + | 24.41 73.76 97.52 | ++ | 50.95 64.40 99.30 | ++ |
Table 3 amycin is to the inhibitory action of cancerous cell
| Positive drug | Final concentration mol/L | Human liver cancer cell SMMC-7721 | The human lung cancer cell A549 | The low differentiation of people adenocarcinoma of stomach cell BGC-823 | Human promyelocytic leukemia cell HL-6 |
| Suppression ratio % | Suppression ratio % | Suppression ratio % | Suppression ratio % | ||
| Amycin | 1×10 -71×10 -61×10 -5 | 10.28 53.40 97.47 | 16.42 16.42 90.44 | 17.86 45.80 97.67 | 61.59 89.73 99.09 |
Table 4 result shows that glycyrrhizin 250 μ mol/L, 500 μ mol/L are respectively 54.5%, 58.1% to the inhibition of stomach cancer cell.
Table 4 glycyrrhizin is to the inhibitory action (48h) of stomach cancer cell (SGC7901)
| Concentration | Glycyrrhizin | |
| The OD value | Suppression ratio (%) | |
| 31.25μmol/L | 0.38±0.01 | -22.6％ ** |
| 62.5μmol/L | 0.35±0.02 | -12.9％ |
| 125μmol/L | 0.37±0.02 | -19.4％ ** |
| 250μmol/L | 0.14±0.01 | 54.8％ ** |
| 500μmol/L | 0.13±0.01 | 58.1％ ** |
| DMSO(1.5％) | 0.31±0.03 | |
| ddH 2O | 0.36±0.03 | |
Compare *＜0.05, * *＜0.01 with DMSO
Table 5 result shows that glycyrrhizin 250 μ mol/L, 500 μ mol/L are respectively 42.0% and 89.9% to the liver cancer cell growth suppression ratio.
The present invention is through extracorporeal anti-tumor screening experiment repeatedly, the flavonoid monomeric compound glycyrrhizin (liquiritigenin) that extracts in the discovery Radix Glycyrrhizae, the SMMC7721 liver cancer cell growth had the obvious suppression effect, glycyrrhizin 200 μ mol/L, 300 μ mol/L, 500 μ mol/L effect hepatoma carcinoma cell 48h, the liver cancer cell growth suppression ratio is respectively 23.5%, 45.2%, 84.0%, and its effect that suppresses tumor is apparently higher than Radix Glycyrrhizae triterpenes monomeric compound glycyrrhizic acid.
Table 5 glycyrrhizin is to the inhibitory action (48h) of hepatoma carcinoma cell (SMMC7721)
| Concentration | Glycyrrhizin | |
| OD value (570nm) | Suppression ratio (%) | |
| 31.25μmol/L | 1.51±0.07 | -9.42％ * |
| 62.5μmol/L | 1.50±0.05 | -8.70％ * |
| 125μmol/L | 1.47±0.06 | -6.52％ |
| 250μmol/L | 0.80±0.29 | 42.0％ ** |
| 500μmol/L | 0.14±0.00 | 89.9％ ** |
| DMSO(1.5％) | 1.38±0.09 | |
| ddH 2O | 1.61±0.14 | |
Compare *＜0.05, * *＜0.01 with DMSO
Table 6 result shows that glycyrrhizin 125 μ mol/L, 250 μ mol/L are respectively 57.6% and 91.9% to the colon cancer cell growth inhibition ratio.
Table 6 glycyrrhizin is to LOVO (colon cancer) cell inhibiting effect (48h)
| Concentration | Glycyrrhizin | |
| OD(570nm) | Suppression ratio | |
| 15.62μmol/L | 1.56±0.06 | 9.3％ * |
| 31.25μmol/L | 1.53±0.03 | 11.0％ ** |
| 62.5μmol/L | 1.25±0.09 | 27.3％ ** |
| 125μmol/L | 0.73±0.05 | 57.6％ ** |
| 250μmol/L | 0.14±0.01 | 91.9％ ** |
| 500μmol/L | 0.14±0.01 | 91.9％ ** |
| 1000μmol/L | 0.12±0.00 | 93％ ** |
| DMSO | 1.72±0.10 | |
| ddH 2O | 1.92±0.10 | |
Compare *＜0.05, * *＜0.01 with DMSO
3.3, conclusion
Glycyrrhizin has the effect of inhibition human liver cancer cell (SMMC7721), human lung cancer cell A549, gastric carcinoma cells (SGC7901), the low differentiation of people adenocarcinoma of stomach cell BGC-823, human colon cancer cell (LOVO), human promyelocytic leukemia cell HL-60 growth.
Claims (6)
1. the application of glycyrrhizin in preparation prevention and treatment curing cancer drug.
2. application according to claim 1, wherein said glycyrrhizin are the flavanone chemical compound.
3. application according to claim 1 and 2, wherein said curing cancer drug are used for the treatment of and prevent pulmonary carcinoma.
4. application according to claim 1 and 2, wherein said curing cancer drug are used for the treatment of and prevent hepatocarcinoma.
5. application according to claim 1 and 2, wherein said curing cancer drug are used for the treatment of and prevent gastric cancer.
6. application according to claim 1 and 2, wherein said curing cancer drug are used for the treatment of and prevent colon cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100388879A CN101036638B (en) | 2006-03-16 | 2006-03-16 | Application of glycyrrhizin in the preparation of medicine for preventing and curing tumour |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100388879A CN101036638B (en) | 2006-03-16 | 2006-03-16 | Application of glycyrrhizin in the preparation of medicine for preventing and curing tumour |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101036638A true CN101036638A (en) | 2007-09-19 |
| CN101036638B CN101036638B (en) | 2011-02-09 |
Family
ID=38887944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100388879A Active CN101036638B (en) | 2006-03-16 | 2006-03-16 | Application of glycyrrhizin in the preparation of medicine for preventing and curing tumour |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101036638B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009031195A1 (en) * | 2007-09-03 | 2009-03-12 | Haruo Higo | Composition containing flavanone compound monomer |
| CN103735497A (en) * | 2013-12-26 | 2014-04-23 | 南京海昌中药集团有限公司 | Liquiritigenin injection and preparation method and application thereof |
| CN104892707A (en) * | 2015-06-11 | 2015-09-09 | 吉林大学 | Compound CLCN based on oriented synthesis and application of CLCN to anti-liver cancer drugs |
| CN109715146A (en) * | 2016-06-02 | 2019-05-03 | 哈佛学院校长同事会 | Eradicate the method and composition of leukaemia cell |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1220518C (en) * | 2002-08-26 | 2005-09-28 | 上海中耀生物科技有限公司 | Chinese medicinal composition for anti-cancer and analgesia, its preparation method and its application in the preparation of product and medicine for treating cancer and analgesia |
-
2006
- 2006-03-16 CN CN2006100388879A patent/CN101036638B/en active Active
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009031195A1 (en) * | 2007-09-03 | 2009-03-12 | Haruo Higo | Composition containing flavanone compound monomer |
| CN103735497A (en) * | 2013-12-26 | 2014-04-23 | 南京海昌中药集团有限公司 | Liquiritigenin injection and preparation method and application thereof |
| CN103735497B (en) * | 2013-12-26 | 2016-04-20 | 南京海昌中药集团有限公司 | Liquiritigenin injection and preparation method thereof and application |
| CN104892707A (en) * | 2015-06-11 | 2015-09-09 | 吉林大学 | Compound CLCN based on oriented synthesis and application of CLCN to anti-liver cancer drugs |
| CN104892707B (en) * | 2015-06-11 | 2017-08-25 | 吉林大学 | A kind of controlled syntheses compound CLCN and its application in medicines resistant to liver cancer |
| CN109715146A (en) * | 2016-06-02 | 2019-05-03 | 哈佛学院校长同事会 | Eradicate the method and composition of leukaemia cell |
| EP3463319A4 (en) * | 2016-06-02 | 2020-02-19 | President and Fellows of Harvard College | Methods and compositions for eradicating leukemic cells |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101036638B (en) | 2011-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wahab et al. | Glycyrrhiza glabra (Licorice): A comprehensive review on its phytochemistry, biological activities, clinical evidence and toxicology | |
| Shahrajabian et al. | A review of Astragalus species as foodstuffs, dietary supplements, a Traditional Chinese Medicine and a part of modern pharmaceutical science. | |
| Hong et al. | Current status of herbal medicines in chronic liver disease therapy: the biological effects, molecular targets and future prospects | |
| Tang et al. | Traditional Tibetan medicine in cancer therapy by targeting apoptosis pathways | |
| Wang et al. | Colon cancer chemopreventive effects of baicalein, an active enteric microbiome metabolite from baicalin | |
| Cheng et al. | Comparative studies of the antiproliferative effects of ginseng polysaccharides on HT-29 human colon cancer cells | |
| Asadi‐Samani et al. | Inhibition of Th1 and Th17 cells by medicinal plants and their derivatives: a systematic review | |
| Chen et al. | Cytotoxic activities of 9, 11-dehydroergosterol peroxide and ergosterol peroxide from the fermentation mycelia of Ganoderma lucidum cultivated in the medium containing leguminous plants on Hep 3B cells | |
| Lee et al. | Ethyl acetate extract from Asparagus cochinchinensis exerts anti‑inflammatory effects in LPS‑stimulated RAW264. 7 macrophage cells by regulating COX‑2/iNOS, inflammatory cytokine expression, MAP kinase pathways, the cell cycle and anti-oxidant activity | |
| Fiorito et al. | Selenylated plant polysaccharides: A survey of their chemical and pharmacological properties | |
| Shen et al. | The dosage-toxicity-efficacy relationship of kansui and licorice in malignant pleural effusion rats based on factor analysis | |
| Kiyama | DNA microarray-based screening and characterization of traditional Chinese medicine | |
| Wang et al. | Bioactive components of Banxia Xiexin Decoction for the treatment of gastrointestinal diseases based on flavor-oriented analysis | |
| CN102133255B (en) | Antineoplastic podophyllum traditional Chinese medicine extract and preparation method and application thereof | |
| Shahrajabian et al. | Astragalus, an ancient medicinal root in traditional Chinese medicine, a gift from silk road | |
| CN101036638A (en) | Application of glycyrrhizin in the preparation of medicine for preventing and curing tumour | |
| Valdés-González et al. | Immunomodulatory, Anti-Inflammatory, and Anti-Cancer Properties of Ginseng: A Pharmacological Update | |
| CN108003214A (en) | A kind of saponin compound and its methods and applications extracted from the rhizoma bolbostemmae | |
| Ahmad | Ganoderma lucidum: a macro fungus with phytochemicals and their pharmacological properties | |
| Yue et al. | Medicinal plants and mushrooms with immunomodulatory and anticancer properties—a review on Hong Kong’s experience | |
| Chang et al. | Total saponins from Rhizoma Panacis Majoris inhibit proliferation, induce cell cycle arrest and apoptosis and influence MAPK signalling pathways on the colorectal cancer cell | |
| Wang et al. | Recent advances in Glycyrrhiza glabra (Licorice)-containing herbs alleviating radiotherapy-and chemotherapy-induced adverse reactions in cancer treatment | |
| Lawal et al. | Bioactive molecules, pharmacology and future research trends of Ganoderma lucidium as a cancer chemotherapeutic agent | |
| Zhang et al. | Development of broad-spectrum antiviral agents—Inspiration from immunomodulatory natural products | |
| Bajek-Bil et al. | Baicalin—Current Trends in Detection Methods and Health-Promoting Properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |